Abstract Number: 1394 • ACR Convergence 2024
Nationwide Retrospective Cohort Study on Clinical Outcomes in Rheumatoid Arthritis Patients Treated with JAK Inhibitors
Background/Purpose: Janus kinase inhibitors (JAKi) are a class of disease activity-modifying drugs (DMARDs) that have quickly established a role in managing rheumatoid arthritis. Inhibition of…Abstract Number: 1597 • ACR Convergence 2024
Baseline Glucocorticoid-Related Toxicity in Newly-Diagnosed and Relapsing ANCA-Associated Vasculitis
Background/Purpose: The ADVOCATE trial evaluated avacopan (a C5a receptor antagonist) as a replacement for a standard prednisone taper in the treatment of granulomatosis with polyangiitis…Abstract Number: 2143 • ACR Convergence 2024
Analysis of Effectiveness and Safety of Romosozumab in Patients with Very High Risk of Fracture in a Spanish Population
Background/Purpose: Excluding clinical trials, there is limited evidence on the effect of 12 months of romosozumab treatment on increasing bone mineral density (BMD) in real-world…Abstract Number: 2366 • ACR Convergence 2024
Improvement in Pain-Associated Biomarkers with Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with PsA in a Double-Blind Phase 2 Study (IM011-084)
Background/Purpose: Pain is a core domain of PsA, and reduction of pain is a primary treatment concern for patients with PsA. Pain has been reported…Abstract Number: 0149 • ACR Convergence 2024
Beliefs on Self-Management in Rheumatoid Arthritis Compared to Other Chronic Diseases Using the Nationally Representative Medical Expenditure Panel Survey
Background/Purpose: Studies that evaluate experiences of living with rheumatoid arthritis (RA) have found that patients identify self-empowerment and a sense of control as important factors…Abstract Number: 0385 • ACR Convergence 2024
Cross-cultural Validation of the “Effects of Youngsters-Eyesight on Quality of Life (EYE-Q)”: A Measure of Vision-related Quality of Life and Function in Childhood Uveitis
Background/Purpose: Childhood uveitis leads to sight-threatening complications in 50% of affected children and significantly impacts a child’s quality of life and function. The Multinational Interdisciplinary…Abstract Number: 0615 • ACR Convergence 2024
Socioeconomic Determinants of Lupus Hospitalization Outcomes: A Review of Current Knowledge and Analysis of the 2016-2019 NRD Database
Background/Purpose: Hospitalizations due to systemic lupus erythematosus (SLE) often stem from lupus flares and infections. Socioeconomic factors influencing outcomes in SLE hospitalizations have been studied…Abstract Number: 0733 • ACR Convergence 2024
Inpatient Outcomes in ANCA-Associated Vasculitis: An In-Depth Cross-Sectional Analysis Using NIS Data (2016-2020)
Background/Purpose: Antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are a heterogeneous group of rare autoimmune conditions characterized by inflammation of blood vessels, leading to various clinical…Abstract Number: 1047 • ACR Convergence 2024
Impact of Treatment Switching on Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus
Background/Purpose: Switching treatment from conventional to biologic disease-modifying antirheumatic drugs (DMARDs) is a common practice for managing autoimmune diseases such as rheumatoid arthritis (RA), psoriatic…Abstract Number: 1403 • ACR Convergence 2024
Development, Validation and Clinical Use of Health-Related Behaviour Health Fitness Questionnaire (HR-BHF) in Indian (Asian) Subjects Attending a Community Rheumatology Center
Background/Purpose: Our patients often express concerns related to ‘wellbeing’ that are not routinely attended during standard care (including QOL). Alternatively, these concerns are important components…Abstract Number: 1598 • ACR Convergence 2024
Projecting the Impact of Standard, Reduced-Dose, and Minimal-Dose Glucocorticoid Regimens in the Treatment of ANCA-Associated Vasculitis Using Simulation Modeling
Background/Purpose: Glucocorticoids (GCs) remain a cornerstone of treatment of ANCA-associated vasculitis (AAV) but predispose people to infectious, metabolic, and other toxicities. We projected the long-term…Abstract Number: 2163 • ACR Convergence 2024
Predictors of Patient Engagement and Usability in a Chronic Musculoskeletal Pain Management App
Background/Purpose: Mobile health apps have demonstrated effectiveness in managing chronic musculoskeletal pain syndromes such as fibromyalgia. We developed an app called POCOS for chronic musculoskeletal…Abstract Number: 2375 • ACR Convergence 2024
Can Damage Items Be Graded According to Severity in a Revised Organ Damage Index for Lupus?
Background/Purpose: The Systemic Lupus International Collaborating Clinics (SLICC), Lupus Foundation of America (LFA), and American College of Rheumatology (ACR) are leading a global initiative to…Abstract Number: 0155 • ACR Convergence 2024
Comparative Analysis and Outcomes of COVID 19: Unveiling Trends in Rheumatological vs. Non-Rheumatological Disease Patients
Background/Purpose: COVID-19 has brought challenges for people with rheumatic diseases as well as those faced by the general population, such as increased risk of SARS-CoV-2…Abstract Number: 0398 • ACR Convergence 2024
Validation of Patient-Reported Outcomes Measurement Information System® (PROMIS®) Pediatric Measures for Children with Chronic Nonbacterial Osteomyelitis Using the CHOIR Data
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease. It is critical to capture the child’s health-related quality of life impact using validated patient-reported…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 49
- Next Page »